International Journal of Medical Evaluation and Physical Report E-ISSN 2579-0498
P-ISSN 2695-2181 Vol 8. No. 6 2024 www.iiardjournals.org Online Version

Incidence of a Fungal Infection in An Individual who has Received a Cancer Diagnosis. (Review Article)

Doaa Abd Alabas Muhammad ridh [1], Fatima Ibrahim Mohammad[2], Osama Faisal Kokaz[3]
[1,2]Department Pathological Analyses, College of Science University of Al_ Qadisiyah, Iraq
[3]Microbiology department, Medicine college, Al_ Muthana University, Al_Samawah, Iraq
Email: duaa.muhammad@qu.edu.iq
DOI: 10.56201/ijmepr.v8.no6.2024.pg36.46

Abstract

UpToDate fungal infections are linked to cancer development in different part of human body. This association frequently seen in individuals has immune system issues and elderly people. Microbial infections in charge of more than 2 million of cancer cases. Invasive fungal infection sustains cancer growth rate and needed to scrutinized. The commonest genus and species of fungi involved are Candida albicans, Candida tropicalis, Aspergillus flavus, Fusarium proliferatum and others. Oral candidiasis consumes the vast majority of oral fungal infections specially when combined with receiving a cancer therapy. This review deals with risk of oral candida and their role in progressing of oral cancer beside co-factors like health status, alcohol, smoking and immune deficiency.

Keywords*: Fungal infection, Candida albicans, Cancers and Candidiasis.*

Introduction

Fungus *Candida albicans* is associated with occurrence of oral tumors and may generate polymicrobial biofilms. that lead to the cancerous transformation of oral keratinocytes, which are epithelial cells that reside in the mouth. Specifically, the effluents produced by biofilms change the ability of oral squamous carcinoma cells to stick to the extracellular matrix and trigger the production of cytokines like IL-6 and IL-8 (Arzmi et al., 2019).

Oral fungal infection is a prevalent opportunistic ailment in the oral cavity resulting from excessive proliferation of fungi. Most of them are classified as Candida species, *C. albicans* being the commonest, up to fifty percent. There have been documented cases of infections (Irani, 2016; Sujir et al., 2019). Non-albicans Candida species comprise *Candida glabrata*, *Candida tropicalis*, and *Candida krusei* (Inchingolo et al., 2020). Mouth candidiasis is the most prevalent mycosis infection which is marked by the appearance of white, smooth patches inside cheeks and tongue. (Mehanna et al., 2013; Panghal et al., 2012). As in figure(A)



Figure (A) Candidiasis in oral cancer patient (Pispero et al., 2022)

Long presence in the critical-care unit, provision of antibiotics with a broad spectrum, anticancer medication, indications of epithelial colonization, use of arterial a catheter, intravenously feeding, and numerous operations requiring stitches (especially those who participated), Candidaemia is more likely to arise after being hospitalized in elderly people, those with existing health conditions, individuals with diabetes, a condition newborn newborns, and people who received transplants (Keighley et al., 2021)

The development of candidiasis and candidemia can result from both internal and external factors. Because *Candida* spp. live on mucosal membranes in the gastroinstinal tract after long-term exposure, which means they come from within, taking broad-spectrum antibiotics can kill off good bacteria and make room for endogenous Candida to grow(Bassetti et al., 2019).

The primary attributes of *Candida albicans*

1- The pathogenicity and cell wall structure

The saprophytic fungus *Candida albicans*, which is a member of the Saccharomycetaceae family, is an inherent part of the human microbiome. It is most commonly found in the mouth, vagina, and gastrointestinal system (Mishra et al., 1992). There are continual variations in the constituents of the cell membrane and the fluidity through which it moves. Proteins, polypeptides, and polysaccharides (including phosphorylated mannans, glucans, and chitins) make up the bulk of the composition(Klis et al., 2009).

The structure of the O- and N-glycosylation bonds that attach the mannan residues to the cell wall might change depending on environmental factors like temperature and pH. Although they are located further inside the wall than mannans, β-Glucans are still there. Phospholipids, sterols, and

ergosterol make up the bulk of lipids' cell walls(Murciano et al., 2011). Many antifungals target these lipids because they are required for the manufacture of enzymes involved in morphogenesis, the process by which the cell wall takes its specific shape. The transformation of yeast into fungus can bring about a lipid alteration (Pan *et al*., 2018) .

Hydrophobicity nature of fungal cells membrane plays a vital role in its capacity to adhere to non-reactive surfaces, and this characteristic can be influenced by the glycosylation of manno-proteins present on its surface. The presence of mannans on the pathogen's surface enhances its pathogenicity by augmenting its hydrophobicity, altering its adhesion to host cells, and suppressing the immune triggers (K. Wang *et al*., 2020).

Candida albicans can propagate as a yeast by the release of quorum sensing chemicals, such as farnesol, while in the hyphal stage. Biofilm acts as a defensive barricade for yeast, shielding cells from the immunological response of the host and rendering them resistant to antifungal medications (Nobile & Johnson, 2015; Taylor et al., 2005).

2- The Genome

The genome replicates itself asexually and is diploid. The "(para)sexuality cycle," a process of divergence that includes mating, recombination, and genomic reduction, occurs in the absence of meiosis. Its capacity to recombine and adapt to different settings is enhanced in this condition, which makes its development and spread easier (Forche et al., 2008; Zhang et al., 2015).

Candida spp. employ serine rather than leucine in their genetic coding through the use of the CUG and CTG codons. As a result, there was a modification in the serine transfer RNA loop, which has the potential to improve resistance to high temperatures (Reedy et al., 2009).

C. albicans, may appeared a wide type of morphologies, including blastoconidia, lengthened pseudohyphae, true hyphae, and even chlamydospores in certain cases. *Candida* species have the potential to cause a range of infections, both sudden and long-lasting, and can become harmful under specific circumstances (opportunism), leading to the development of candidiasis. This condition is most prevalent among patients with weakened immune systems (Talapko et al., 2021). Bloating in the abdomen, slow digestion, gastrointestinal problems (such as stultification or diarrhea), fatigue, irritability, food sensitivities, insomnia, depression cognitive decline, and headaches are some of the symptoms that can occur when candida enters the bloodstream through the stomach (Tortorano et al., 2004).

Possible causes of oral candidiasis include impaired salivary gland function, specific medicines, a food stuff with carbohydrates and artificial prosthetics. Additionally, smoking, diabetes, immunosuppression and cancers are particularly significant factors in the development of oral candidiasis. Inhalations of corticosteroids have been correlated to an elevated risk of oral candidiasis, as they hinder immune system function and internalization. When steroid inhalation stops, the mucosa's normal immune response takes over. Antibiotics with a broad spectrum of

action can damage the oral flora in the area, which can make Candida thrive. Dental components that produce an acidic pH and low oxygen levels foster the formation of Candida infections. In addition to promoting *Candida* growing in saliva as well as adhesion to oral epithalamium, a sugars-rich diet (Ghannoum et al., 2010; Kabir & Ahmad, 2013; Patil et al., 2015).

An expanding number of *Candida* spp. in both healthy and periodontally affected areas were found to be correlated. Despite this, fungal total compositions varied (Peters et al., 2017).

C. albicans induces invasive hyphae by the secretion of interlukine1β, triggers the activation of pro-inflammatory cytokine. The genetic analysis showed significant colonization in genotype A of *C. albicans*. Studies indicate that differences in genetic makeup within oral squamous cell carcinoma can influence the development of cancer (Birman et al., 1997).

Study of Oral Candidiasis via Mycological Investigation

Diagnosis is possible for every form of oral candidiasis. which can be enhanced by further diagnostic methods, such as isolation in culture and microscopy, are used to diagnose Candida in oral samples. It is crucial to identify the high-risk locations for yeast infection, including the corners of the lips, cheek wall, behind the commissure, posterior median section of the back of the tongue, and palate. Upon direct examination of candida smears, it was seen that there were oval or spherical components present, which exhibited budding. Mycelial filaments can exhibit either irregular or regular patterns (Mohamed et al., 2019).

Upon direct inspection, several fungal components are observed. Nevertheless, the accuracy of diagnosis can be enhanced by cultivating in particular settings such as Sabouraud and Micro Stix (Bornstein, 2019). *Candida albicans*, present in the oral cavity as spores or filaments, is an inherent component of the oral microbiota and does not provide any health hazards. In order to identify candidiasis, a substantial quantity of colonies or filaments on smears is necessary (Kumar et al., 2014). Culture is a fundamental method for detecting fungal infections. The lack of cultural sensitivity Delaying the completion of treatment for invasive candidiasis (IC) can result in increased mortality rates (Fortún et al., 2012).

Although blood culture is considered the most reliable method for diagnosing invasive fungal infections, its diagnostic process can be expedited by combining it with other tests. These assays possess the capability to identify IC at an early stage, particularly in situations when culture is unable to detect it. PCR techniques empower swift, also precise identification and finding of fungal genome in human samples, obviating the necessity for preceding cultures. PCR techniques may identify the presence of fungus in several types of materials, such as plasma, serum, blood, sterile fluids, bronchoalveolar lavage (BAL), and soft tissues. This is achieved by focusing on specific genetic sequences, such as 18S rDNA, 5.8S rDNA, and 28S rDNA. Scientists have created internal transcribed spacer regions and mitochondrial DNA. Fungal infections can be diagnosed within individuals(Posch et al., 2017).

The role of Candida in oral cancer

More than 90% of oral malignancies are cutaneous squamous cell carcinomas. (Abati et al., 2020; Markopoulos, 2012). The condition may manifest on the lips, mouth cavity, or tongue, in addition to other areas within the oral cavity. More than 50% casing of oral plano-cellular carcinomata are caused by precancerous lesioned on mucosa, such as leukoplakia or erythroplakia increases mortality nearly 50% (Inchingolo *et al*., 2020; Sujir et al., 2019).

For quite some time, people have argued about whether or not *Candida* spp. causes oral cancer. Researches indicates that this particular kind of fungi can accelerate the progression of mouth cancer. (Di Cosola et al., 2021; Sultan et al., 2022). Mouth cells' genetic instability, epithelium transformation, oncogenic effects, Immunol system regulation, and habitual inflammation are the mechanisms that have been suggested to lead to mouth cancer (Vadovics *et al*., 2022; Yu & Liu, 2022). Oral *C. albicans* residents may be allied with a progressive risk of oral carcinoma, depending on a recent metadata analysis. This is brought about by alterations in the cell's phenotypic structure (Ayuningtyas *et al*., 2022). It's known that *C. albicans* can produce carcinogenic chemicals, which can increase the risk of oral cancer (Abati et al., 2020). Cancer cells infected with *Candida albicans* had their gene expression levels elevated, these genes are involved in cell cycle control, inflammation response, and mesenchymal cell transition. Oral squamous cell carcinoma progression may be aided by *Candida albicans*, which may affect therapeutic methods by enhancing a precancerous feature and raising oncogene expression (Vadovics et al., 2022). Candida albicans upregulates IL-17A and its receptor, IL-17RA, when it infects macrophages and oral cancer cells. Next, macrophage activation occurs as a result of elevated IL-17A/IL-17RA signaling, leading to enhanced Inflammatory cytokines facilitate cell proliferation, metastasis, and invasion in oral cancer (X. Wang et al., 2023). This connotation is extra supported via other studies, by using single-cell expression profiling and producing carcinogenic enzymes, *Candida albicans* damages DNA, allowing cancer cells to proliferate and survive, ultimately causing mouth cancer. Certain chemicals are present included in this group are nitrosamines and acetaldehyde (Bakri et al., 2010; Krogh et al., 1987). It is worth mentioning that Oral *Candida* have the capacity to transform alcohol into acetaldehyde. Acetaldehyde induces genome mutilation also inhibits DNA reparation, resulting to chromosomal aberrations and mutations that are allied with the cancer progress (Mizumoto *et al*., 2017). This molecule indirectly binds to glutathione, an antioxidant, resulting in increased levels of reactive oxygen species, prolonged inflammation, and impaired mitochondrial function. *Candida albicans* infection lowers immune system function and increases cancer risk. The enzyme apoptosis is important for removing unhealthy cells from the body, but this fungus can prevent it from happening. The development of cancer may ensue from this (Richardson & Moyes, 2015). Candidalysin, a virulence factor of *Candida albicans*, may potentially have a role in the progression of oral cancer. Oral candidiasis is a prevalent fungal infection caused by the protein toxin candidlysin, which is secreted by the fungus Candida albicans. Oral infection. articles designate that candidalysin could involve in the initial phases of oral cavity cancer progression, however its specific function remains uncertain (Findley et al., 2013).

Research suggests that candidalysin possesses oncogenic qualities as it can stimulate the immune system and induce inflammation, potentially proceeds to the expansion of cancer. Data have also demonstrate candidalysin has the ability to impair the decency of mouth epithelial cell membranes, harm DNA, besides induce mutations upon interaction with these cell surfaces (Mahalingam et al., 2022).

Therapies

Treatment might be either regional or systemic. Despite its success, immunosuppression frequently results in the reappearance of the condition. Common therapies encompass the subsequent: - Administer AMPHOTERICIN B tablets at a dosage of 10-100mg every 6 hours. The recommended dosage for MICONAZOLE tablets is 250mg every 6 hours. Administer KETOCONAZOLE tablets at a dosage of 200-400 mg each day. Take FLUCONAZOLE tablets at a dosage of 50-100 mg each day. Therapy using KETOCONAZOLE has experienced failures. It has substantial adverse consequences, such as repeated liver damage (Lam-ubol et al., 2019; Rafat et al., 2021). Moreover, FLUCONAZOLE seems to be the medication that is best tolerated by those who are HIV-positive. It exhibits greater efficacy compared to other antifungal agents. It is more efficiently absorbed in the gastrointestinal tract. In addition, administering a weekly dosage of 150 mg has proven to be efficacious for preventive measures, leading to an extended lifespan while causing few negative consequences. In addition, it is effective in treating oral candidiasis without affecting taste, and its salivary level is consistent with the serum level (Goldman et al., 2005; Osaigbovo et al., 2017; Wassano et al., 2020).

Conclusion

Oral fungal colonization elevated the risk of cancer which can be expanding to through oral cavity to esophagus or systemic infection. Yeast *C. albicans* specifically the most common species which abundant in oral squamous cell cancer patients. Health care providers indeed invited to aware of fungal infection management that can be face the consequences of this fragile item.

References

Abati, S., Bramati, C., Bondi, S., Lissoni, A., & Trimarchi, M. (2020). Oral cancer and precancer: A narrative review on the relevance of early diagnosis. *International Journal of Environmental Research and Public Health*, *17*(24), 1–14. https://doi.org/10.3390/ijerph17249160

Arzmi, M. H., Cirillo, N., Lenzo, J. C., Catmull, D. V., O'Brien-Simpson, N., Reynolds, E. C., Dashper, S., & McCullough, M. (2019). Monospecies and polymicrobial biofilms differentially regulate the phenotype of genotype-specific oral cancer cells. *Carcinogenesis*, *40*(1), 184–193. https://doi.org/10.1093/carcin/bgy137

Ayuningtyas, N. F., Mahdani, F. Y., Pasaribu, T. A. S., Chalim, M., Ayna, V. K. P., Santosh, A.

B. R., Santacroce, L., & Surboyo, M. D. C. (2022). Role of Candida albicans in Oral Carcinogenesis. *Pathophysiology*, *29*(4), 650–662. https://doi.org/10.3390/pathophysiology29040051

Bakri, M. M., Hussaini, H. M., Holmes, A., Cannon, R. D., & Rich, A. M. (2010). Revisiting the association between candidal infection and carcinoma, particularly oral squamous cell carcinoma. *Journal of Oral Microbiology*, *2*(2010). https://doi.org/10.3402/jom.v2i0.5780

Bassetti, M., Giacobbe, D. R., Vena, A., & Wolff, M. (2019). Diagnosis and Treatment of Candidemia in the Intensive Care Unit. *Seminars in Respiratory and Critical Care Medicine*, *40*(4), 524–539. https://doi.org/10.1055/s-0039-1693704

Birman, E. G., Kignel, S., Da Silveira, F. R. X., & Paula, C. R. (1997). Candida albicans: Frequency and characterization in oral cancer (Stage I) from smokers and drinkers. *Revista Iberoamericana de Micologia*, *14*(3), 101–103.

Bornstein, J. (2019). Vulvar Disease: Breaking the Myths. In *Vulvar Disease: Breaking the Myths* (Issue Vvc). https://doi.org/10.1007/978-3-319-61621-6

Di Cosola, M., Cazzolla, A. P., Charitos, I. A., Ballini, A., Inchingolo, F., & Santacroce, L. (2021). Candida albicans and oral carcinogenesis. A brief review. *Journal of Fungi*, *7*(6). https://doi.org/10.3390/jof7060476

Findley, K., Oh, J., Yang, J., Conlan, S., Deming, C., Meyer, J. A., Schoenfeld, D., Nomicos, E., Park, M., Becker, J., Benjamin, B., Blakesley, R., Bouffard, G., Brooks, S., Coleman, H., Dekhtyar, M., Gregory, M., Guan, X., Gupta, J., … Segre, J. A. (2013). Topographic diversity of fungal and bacterial communities in human skin. *Nature*, *498*(7454), 367–370. https://doi.org/10.1038/nature12171

Forche, A., Alby, K., Schaefer, D., Johnson, A. D., Berman, J., & Bennett, R. J. (2008). The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains. *PLoS Biology*, *6*(5), 1084–1097. https://doi.org/10.1371/journal.pbio.0060110

Fortún, J., Martín-Dávila, P., Gómez-García de la Pedrosa, E., Pintado, V., Cobo, J., Fresco, G., Meije, Y., Ros, L., Alvarez, M. E., Luengo, J., Agundez, M., Belso, A., Sánchez-Sousa, A., Loza, E., & Moreno, S. (2012). Emerging trends in candidemia: A higher incidence but a similar outcome. *Journal of Infection*, *65*(1), 64–70. https://doi.org/10.1016/j.jinf.2012.02.011

Ghannoum, M. A., Jurevic, R. J., Mukherjee, P. K., Cui, F., Sikaroodi, M., Naqvi, A., & Gillevet, P. M. (2010). Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathogens*, *6*(1). https://doi.org/10.1371/journal.ppat.1000713

Goldman, M., Cloud, G. A., Wade, K. D., Reboli, A. C., Fichtenbaum, C. J., Hafner, R., Sobel, J. D., Powderly, W. G., Patterson, T. F., Wheat, L. J., Stein, D. K., & Dismukes, W. E. (2005). A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS clinical trials group study 323/mycoses study group study 40. *Clinical Infectious Diseases*, *41*(10), 1473–1480. https://doi.org/10.1086/497373

Inchingolo, F., Santacroce, L., Ballini, A., Topi, S., Dipalma, G., Haxhirexha, K., Bottalico, L., & Charitos, I. A. (2020). Oral cancer: A historical review. *International Journal of Environmental Research and Public Health*, *17*(9). https://doi.org/10.3390/ijerph17093168

Irani, S. (2016). Pre-Cancerous Lesions in the Oral and Maxillofacial Region: A Literature Review with Special Focus on Etiopathogenesis. *Iranian Journal of Pathology*, *11*(4), 303–322.

Kabir, M. A., & Ahmad, Z. (2013). Candida Infections and Their Prevention . *ISRN Preventive Medicine*, *2013*(Vvc), 1–13. https://doi.org/10.5402/2013/763628

Keighley, C. L., Pope, A., Marriott, D. J. E., Chapman, B., Bak, N., Daveson, K., Hajkowicz, K., Halliday, C., Kennedy, K., Kidd, S., Sorrell, T. C., Underwood, N., van Hal, S., Slavin, M. A., & Chen, S. C. A. (2021). Risk factors for candidaemia: A prospective multi-centre case-control study. *Mycoses*, *64*(3), 257–263. https://doi.org/10.1111/myc.13211

Klis, F. M., Sosinska, G. J., De Groot, P. W. J., & Brul, S. (2009). Covalently linked cell wall proteins of Candida albicans and their role in fitness and virulence. *FEMS Yeast Research*, *9*(7), 1013–1028. https://doi.org/10.1111/j.1567-1364.2009.00541.x

Krogh, P., Hald, B., & Holmstrup, P. (1987). Possible mycological etiology of oral mucosal cancer: Catalytic potential of infecting candida aibicans and other yeasts in production of N-nitrosobenzylmethylamine. *Carcinogenesis*, *8*(10), 1543–1548. https://doi.org/10.1093/carcin/8.10.1543

Kumar, S., Mishra, P., Warhekar, S., Airen, B., Jain, D., & Godha, S. (2014). Oral health status and oromucosal lesions in patients living with HIV/AIDS in India: A comparative study. *AIDS Research and Treatment*, *2014*. https://doi.org/10.1155/2014/480247

Lam-ubol, A., Rungsiyanont, S., Vacharotayangul, P., Sappayatosok, K., & Chankanka, O. (2019). Oral manifestations, salivary flow rates and Candida species in Thai HIV-infected patients. *Journal of Clinical and Experimental Dentistry*, *11*(2), e138–e145. https://doi.org/10.4317/jced.55384

Mahalingam, S. S., Jayaraman, S., & Pandiyan, P. (2022). Fungal Colonization and Infections—Interactions with Other Human Diseases. *Pathogens*, *11*(2), 1–16. https://doi.org/10.3390/pathogens11020212

Markopoulos, A. K. (2012). Current Aspects on Oral Squamous Cell Carcinoma. *The Open Dentistry Journal*, *6*(1), 126–130. https://doi.org/10.2174/1874210601206010126

Mehanna, H., Beech, T., Nicholson, T., El-Hariry, I., McConkey, C., Paleri, V., & Roberts, S. (2013). Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. *Head and Neck*, *35*(10), 1391. https://doi.org/10.1002/HED

Mishra, P., Bolard, J., & Prasad, R. (1992). Emerging role of lipids of Candida albicans, a pathogenic dimorphic yeast. *Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism*, *1127*(1), 1–14. https://doi.org/10.1016/0005-2760(92)90194-Z

Mizumoto, A., Ohashi, S., Hirohashi, K., Amanuma, Y., Matsuda, T., & Muto, M. (2017). Molecular mechanisms of acetaldehyde-mediated carcinogenesis in squamous epithelium. *International Journal of Molecular Sciences*, *18*(9), 1–12. https://doi.org/10.3390/ijms18091943

Mohamed, A. A., Lu, X. L., & Mounmin, F. A. (2019). Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. *Canadian Journal of Gastroenterology and Hepatology*, *2019*. https://doi.org/10.1155/2019/3585136

Murciano, C., Moyes, D. L., Runglall, M., Islam, A., Mille, C., Fradin, C., Poulain, D., Gow, N. A. R., & Naglik, J. R. (2011). Candida albicans cell wall glycosylation may be indirectly required for activation of epithelial cell proinflammatory responses. *Infection and Immunity*, *79*(12), 4902–4911. https://doi.org/10.1128/IAI.05591-11

Nobile, C. J., & Johnson, A. D. (2015). Candida albicans Biofilms and Human Disease. *Annual Review of Microbiology*, *69*(1), 71–92. https://doi.org/10.1146/annurev-micro-091014-104330

Osaigbovo, I. I., Lofor, P. V., & Oladele, R. O. (2017). Fluconazole resistance among oral Candida isolates from people living with HIV/AIDS in a Nigerian tertiary hospital. *Journal of Fungi*, *3*(4). https://doi.org/10.3390/jof3040069

Pan, J., Hu, C., & Yu, J. H. (2018). Lipid biosynthesis as an antifungal target. *Journal of Fungi*, *4*(2), 1–13. https://doi.org/10.3390/jof4020050

Panghal, M., Kaushal, V., Kadayan, S., & Yadav, J. P. (2012). Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. *BMC Oral Health*, *12*(1). https://doi.org/10.1186/1472-6831-12-22

Patil, S., Rao, R. S., Majumdar, B., & Anil, S. (2015). Clinical appearance of oral Candida infection and therapeutic strategies. *Frontiers in Microbiology*, *6*(DEC), 1–10.

https://doi.org/10.3389/fmicb.2015.01391

Peters, B. A., Wu, J., Hayes, R. B., & Ahn, J. (2017). The oral fungal mycobiome: Characteristics and relation to periodontitis in a pilot study. *BMC Microbiology*, *17*(1), 1–11. https://doi.org/10.1186/s12866-017-1064-9

Pispero, A., Lombardi, N., Manfredi, M., Varoni, E. M., Sardella, A., & Lodi, G. (2022). Oral infections in oral cancer survivors: A mini-review. *Frontiers in Oral Health*, *3*(October), 1–8. https://doi.org/10.3389/froh.2022.970074

Posch, W., Heimdörfer, D., Wilflingseder, D., & Lass-Flörl, C. (2017). Invasive candidiasis: future directions in non-culture based diagnosis. *Expert Review of Anti-Infective Therapy*, *15*(9), 829–838. https://doi.org/10.1080/14787210.2017.1370373

Rafat, Z., Sasani, E., Salimi, Y., Hajimohammadi, S., Shenagari, M., & Roostaei, D. (2021). The Prevalence, Etiological Agents, Clinical Features, Treatment, and Diagnosis of HIV-Associated Oral Candidiasis in Pediatrics Across the World: A Systematic Review and Meta-Analysis. *Frontiers in Pediatrics*, *9*(December). https://doi.org/10.3389/fped.2021.805527

Reedy, J. L., Floyd, A. M., & Heitman, J. (2009). Mechanistic Plasticity of Sexual Reproduction and Meiosis in the Candida Pathogenic Species Complex. *Current Biology*, *19*(11), 891–899. https://doi.org/10.1016/j.cub.2009.04.058

Richardson, J. P., & Moyes, D. L. (2015). Adaptive immune responses to Candida albicans infection. *Virulence*, *6*(4), 327–337. https://doi.org/10.1080/21505594.2015.1004977

Sujir, N., Ahmed, J., Pai, K., Denny, C., & Shenoy, N. (2019). Challenges in early diagnosis of oral cancer: Cases Series. *Acta Stomatologica Croatica*, *53*(2), 174–180. https://doi.org/10.15644/asc53/2/10

Sultan, A. S., Theofilou, V. I., Alfaifi, A., Montelongo-Jauregui, D., & Jabra-Rizk, M. A. (2022). Is Candida albicans an opportunistic oncogenic pathogen? *PLoS Pathogens*, *18*(4), 1–8. https://doi.org/10.1371/journal.ppat.1010413

Talapko, J., Juzbašić, M., Matijević, T., Pustijanac, E., Bekić, S., Kotris, I., & Škrlec, I. (2021). Candida albicans-the virulence factors and clinical manifestations of infection. *Journal of Fungi*, *7*(2), 1–19. https://doi.org/10.3390/jof7020079

Taylor, B. N., Hannemann, H., Sehnal, M., Biesemeier, A., Schweizer, A., Röllinghoff, M., & Schröppel, K. (2005). Induction of SAP7 correlates with virulence in an intravenous infection model of candidiasis but not in a vaginal infection model in mice. *Infection and Immunity*, *73*(10), 7061–7063. https://doi.org/10.1128/IAI.73.10.7061-7063.2005

Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., & Grillot, R. (2004). Epidemiology of candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. *European Journal of Clinical Microbiology and Infectious Diseases*, *23*(4), 317–322. https://doi.org/10.1007/s10096-004-1103-y

Vadovics, M., Jemima, H., Igaz, N., Alfodi, R., Horvath, M., Henley-smith, R., Moyes, D. L., Thavaraj, S., & Naglik, J. R. (2022). Candida albicans Enhances the Progression of Oral Squamous. *American Society for Microbiology*, *October 2021*, 1–21.

Wang, K., Luo, Y., Zhang, W., Xie, S., Yan, P., Liu, Y., Li, Y., Ma, X., Xiao, K., Fu, H., Cai, J., & Xie, L. (2020). Diagnostic value of Candida mannan antigen and anti-mannan IgG and IgM antibodies for Candida infection. *Mycoses*, *63*(2), 181–188. https://doi.org/10.1111/myc.13035

Wang, X., Wu, S., Wu, W., Zhang, W., Li, L., Liu, Q., & Yan, Z. (2023). Candida albicans Promotes Oral Cancer via IL-17A/IL-17RAMacrophage Axis. *MBio*, *14*(3). https://doi.org/10.1128/mbio.00447-23

Wassano, N. S., Goldman, G. H., & Damasio, A. (2020). Aspergillus fumigatus. *Trends in Microbiology*, *28*(7), 594–595. https://doi.org/10.1016/j.tim.2020.02.013

Yu, D., & Liu, Z. (2022). The research progress in the interaction between Candida albicans and cancers. *Frontiers in Microbiology*, *13*(September), 1–10. https://doi.org/10.3389/fmicb.2022.988734

Zhang, N., Magee, B. B., Magee, P. T., Holland, B. R., Rodrigues, E., Holmes, A. R., Cannon, R. D., & Schmid, J. (2015). Selective advantages of a parasexual cycle for the yeast Candida albicans. *Genetics*, *200*(4), 1117–1132. https://doi.org/10.1534/genetics.115.177170